
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is adjusting its FY26 EPS estimates upwards, reflecting an improved outlook with a projected loss of $(4.17) compared to the previous estimate of $(8.63), indicating a positive trajectory in financial performance despite ongoing losses. The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud software platform and expected FDA approval of its first diagnostic algorithm by the first half of 2026, positions the company to capitalize on a substantial market opportunity. These developments suggest a strategic enhancement of HeartSciences's offerings, making it well-poised to become a significant player in the cardiac screening technology space.
Bears say
HeartSciences Inc is currently facing significant risks that could negatively impact its stock performance, including balance sheet and liquidity challenges, as well as the potential failure of its product candidates to demonstrate necessary safety and efficacy in clinical trials. Furthermore, the company has revised its FY2026 revenue estimate downward from $1.2 million to $0.1 million, primarily due to delays in obtaining FDA approvals, signaling potential difficulties in product commercialization and reimbursement processes. Additionally, external factors such as competition, macroeconomic conditions, and fluctuating investor sentiment towards healthcare stocks further complicate the company’s growth prospects and contribute to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares